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Abstract. Establishment and maintenance of the apical-
basal cell polarity, required for proper replication, migration, 
specialized functions and tissue morphogenesis, relies on 
three evolutionary conserved complexes: PAR, CRUMBS and 
SCRIBBLE. Loss of cell polarity/cohesiveness (LOP/C) is 
implicated in cancer progression, and members of the polarity 
complex have been described as either oncogenes or oncosup-
pressors. However, no information on their role in thyroid 
cancer (TC) progression is available. In the present study, we 
evaluated the gene expression of the PAR complex members 
aPKCι, PARD3α/β and PARD6α/β/γ in 95 papillary TC (PTC), 
compared to their normal matched tissues and in 12 anaplastic 
TC (ATC). The mRNA and protein levels of investigated genes 
were altered in the majority of PTC and ATC tissues. In PTC, 
univariate analysis showed that reduced expression of aPKCι, 
PARD3β and PARD6γ mRNAs is associated with increased 
tumor size, and the reduced expression of PARD3β mRNA is 
associated also with recurrences. Multivariate analysis demon-
strated that the presence of lymph node metastasis at diagnosis 
and the reduced expression of PARD3β are independent risk 
factors for recurrences, with hazard ratio, respectively, of 8.21 
(P=0.006) and 3.04 (P=0.029). The latter result was confirmed 
by the Kaplan-Meier analysis, which evidenced the asso-
ciation between decreased PARD3β mRNA levels and shorter 
disease-free interval. In conclusion, we demonstrated that the 
expression of PAR complex components is deregulated in the 
majority of PTC and there is a general trend towards their 
reduction in ATC tissues. Moreover, a prognostic value for the 
PARD3β gene in PTCs is suggested.
Introduction
Polarity is defined as the persistent asymmetrical and ordered 
distribution of structures along an axis, and represents a basic 
property of organisms, organs, tissues and cells (1). Different 
types of polarity exist, like the planar cell polarity (PCP), the 
apical-basal polarity (ABP) and the front-rear polarity (FRP). 
The ABP is the most studied and best described type of cell 
polarity, and is a peculiar characteristic of epithelial and endo-
thelial cells (2). It determines the formation of two cellular 
regions: the apical one faces the lumen and the basal one is in 
contact with the basement membrane. The establishment and 
maintenance of ABP is due to the interaction and subcellular 
localization of three evolutionary conserved protein complexes, 
CRUMBS, PAR and SCRIBBLE, that determine the domains 
of polarized cells, i.e. the apical, the apical-lateral and the basal-
lateral districts, respectively. The three polarity complexes 
participate also in the formation and stabilization of the tight 
junctions (TJs) and adherent junctions (AJs), which in turn have 
a role in preserving the ABP and tissue homeostasis (3-6).
Over the last decades, various research has clarified the 
role of the polarity complexes starting from the study of the 
model organisms Caenorhabditis elegans and Drosophila 
melanogaster (7-9). The comprehension of the molecular 
functions of these complexes led to consider cell polarity the 
prerequisite for the organogenesis, and essential to ensure tissue 
homeostasis by controlling proliferation, asymmetric division, 
migration and specialized cell functions (5). Not surprisingly, 
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both neoplastic transformation and cancer progression have 
been associated to loss of cell polarity/cohesiveness (LOP/C), 
considered a cancer hallmark (10). Moreover, LOP/C is impli-
cated in the epithelial-mesenchymal transition (EMT), strictly 
connected with the metastasis development (10). Deregulated 
expression of ABP complex members has been described in 
several cancer types, in which they have been identified as 
either oncosuppressors or oncogenes (4).
In the present study, we focused attention on the one having 
the widest range of functions, i.e. the PAR (PARtitioning defec-
tive) complex (11). It is composed by a core of three proteins: 
PAR3, PAR6 and the atypical protein kinase C, aPKC. In 
mammals, paralogous genes have been described: PARD3α/β, 
PARD6α/β/γ, aPKCζ and aPKCι, expressed at different levels 
during the embryonal development and in adult tissues (12-15). 
PARD3α localizes at TJs formation areas and acts as scaffold 
for aPKC and PARD6 to induce TJs assembly, but participates 
also in the regulation of other cellular processes, including 
migration, cell cycle and asymmetrical division by interacting 
with other molecules (5). PARD3β does not interact with 
the aPKC, although sharing the cellular localization with 
PARD3α, thus, it does not seem to participate in formation 
of TJs (3,16). Regarding the three PARD6 forms, PARD6α is 
present both at TJs and in the cytosol, PARD6β is localized 
in the cytosol and PARD6γ focuses at TJs. Some studies have 
described other cellular locations of PARD6α and PARD6γ, 
that is nucleus and centriole, respectively (17,18). Like PARD3, 
PARD6 acts as scaffold protein, and its principal role is to 
connect aPKC to PARD3α and to its downstream targets, 
but the different subcellular localizations of the three forms 
indicate further functions (17,18). Proteins aPKCζ and aPKCι 
are both localized in the cytoplasm and at the TJs, and phos-
phorylate numerous substrates, among which PARD3 (3).
Alterations in the expression levels of the PAR complex 
members have been reported in many types of human cancer, 
like the esophageal squamous cell carcinoma, the non-small 
cell lung carcinoma, the ovarian cancer and the breast 
carcinoma (19). Moreover, an oncogenic/oncosuppressor 
context-dependent role of PAR members emerged from func-
tional studies (19). However, there is a lack of information on 
PAR gene expression and role in epithelial thyroid cancer (TC) 
progression.
TC represents the most common endocrine malignancy 
accounting for roughly 1% of all human cancers, and its inci-
dence has been increasing over the last decades, mainly due 
to the improved ability to diagnose malignant transformation 
in small non-palpable thyroid nodules (20,21). More than 90% 
of thyroid carcinomas are represented by the differentiated 
papillary (PTC) and follicular (FTC) histotypes, whereas the 
invariably fatal undifferentiated (anaplastic) thyroid carci-
noma (ATC) accounts for aproximately 1% of TC (22,23). 
Although derived from the same cell type, the epithelial 
thyroid tumors show specific histological features, biological 
behavior and degree of differentiation as a consequence of 
different genetic alterations (24,25). One of the most common 
in PTC is the BRAFV600E mutation (26,27), that associates 
with clinicopathological features, as advanced stage, extra-
thyroidal extension, lymph node and distant metastases (28). 
Some authors evidenced polarity alterations in TC, and it has 
been shown that PTC patients with tumors retaining cellular 
polarity had a better course than those exhibiting LOP/C 
features (29-31).
In the present study, we analyzed the expression of the 
PAR complex members in 95 PTC compared against normal 
tissues and 12 ATC tissues. Data from PTC patients were then 
correlated with clinicopathological parameters and patients' 
disease-free interval.
Materials and methods
Tissue samples, histology and staging of patients. Normal and 
matched PTC tissues were obtained from surgical specimens 
of 95 patients (19 males and 76 females, age range 11-83 
years, median 44 years) who underwent total thyroidectomy 
at the Department of Surgical Sciences, ‘Sapienza’ University 
of Rome (38 patients) or at the Department of Medicine, 
University of Padua (57 patients); while ATC tissues were 
collected from surgical specimens of 12 patients (4 males and 
8 females, age range 57-79 years, median 69 years) who had 
surgery at the Department of Medicine, University of Padua 
(7 patients) or at Department of Clinical and Experimental 
Medicine of Pisa (5 patients). All the patients gave their 
informed consent, and the study was approved by the local 
ethics committee (protocol no. 2615). Tissue samples were 
collected, frozen in liquid nitrogen and stored at -80˚C. Of the 
95 patients, 72 exhibited classical, 18 follicular, 2 tall cell and 
2 oncocytic variants. The histological diagnoses were made 
independently by two different histopathologists according 
to the World Health Organization classification (32). At the 
time of surgery lymph node metastases were found in 39 
patients. Following TNM staging, 59 patients were at stage I, 
1 at stage II, 29 at stage III and 6 at stage Iv. Approximately 
40-50 days later all the patients underwent radioiodine therapy 
followed by thyroid hormone replacement therapy. To ascer-
tain their disease-free condition, 4-5 months after intervention 
all the patients underwent neck ultrasound and serum Tg 
measurement. Recurrences were diagnosed by measurement 
of serum Tg levels either in basal conditions or following 
recombinant human TSH stimulation; FNA cytology and/or 
Tg determination in the FNA wash-out from lymph nodes; 
131I whole body scan; histological analysis following surgical 
resection of the lesion. The follow-up included 79 patients 
(mean 57.1±36.7 months, range 5-141 months), 52 of whom 
were at TNM stage I. During the follow-up 16 recurrences 
were recorded. Regarding ATC patients, they all died from the 
disease (survival time range 1-25 months, median 6 months).
Determination of BRAFV600E mutation. Genomic DNA was 
extracted from the frozen tissues using the DNeasy Blood and 
Tissues kit (Qiagen, Milan, Italy) according to the manufac-
turer's protocol. The BRAF status of exon 15 was assessed by 
both direct sequencing and mutant allele-specific PCR ampli-
fication for the T to A substitution at nucleotide 1799 (V600E), 
using the procedure previously described (33).
Extraction and analysis of mRNA. Frozen normal and tumor 
thyroid tissues were homogenized with the ultra-turrax, and 
total RNA extracted applying the acid guanidinium thiocya-
nate-phenol-chloroform method (34). The first cDNA strand 
was synthesized from 5 µg of RNA with M-MLv reverse 
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transcriptase and anchored oligo(dT)23 primers (Sigma 
Chemicals). Parallel controls for DNA contamination were 
carried out omitting the reverse transcriptase. The templates 
obtained were used for quantitative PCR amplifications of the 
different members of the PAR complex and three different 
housekeeping genes (GAPDH, RPL13A and SDHA), previ-
ously shown to be the most stable among 7 candidate reference 
genes (35,36), employing the LightCycler instrument (Roche 
Diagnostics, Mannheim, Germany), the SYBR Premix Ex 
Taq II (Tli RNase H Plus) (Takara, Shiga, Japan) and specific 
primers listed in Table I. Amplicon specificities were checked 
by automated DNA sequencing (Bio-Fab Research, Rome, 
Italy), evaluation of melting temperatures, and electrophoresis 
on 2% agarose gel containing ethidium bromide. Standard 
curves for all genes were created with 5-fold dilutions of 
mixed human thyroid tissue cDNA. Calculation of data for 
PTC was performed by the Relative Expression Software 
Tool (REST 2009) using a normalization factor computed as 
the geometric media of the 3 reference genes, as previously 
described (35,36). The fold change in the mRNA levels of the 
different PAR complex components was referred for each PTC 
sample to its normal counterpart. Regarding ATC samples, 
for which the normal matched tissues were not available, they 
were compared to PTC tissues through the ∆∆Ct method. 
In the latter, the ∆Ct of each gene was calculated using the 
geometric mean of the above mentioned housekeeping genes, 
whose expression was proven to be stable also between PTC 
and ATC in preliminary experiments (data not shown). The 
∆∆Ct were computed by subtracting the ∆Ct of each sample 
the ∆Ct of the sample showing the lowest gene expression (37).
Western blot analysis. Normal and PTC tissue samples from 12 
patients were homogenized in RIPA buffer (50 mM Tris-HCl 
pH 7.4, 1% NP-40, 0.5% sodium deoxycholate, 150 mM 
sodium chloride, 1 mM EDTA, 1 mM sodium fluoride, 1 mM 
AEBSF, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 1 mM sodium 
orthovanadate, 10 mM sodium pyrophosphate in ddH2O) by 
Turrax, centrifuged at 10,000 rpm for 10 min and frozen to 
-80˚C. Protein concentrations in the cell extracts were deter-
mined by the Bradford assay (38). Aliquot of 50 µg of tissue 
extracts were supplemented with 5X Laemmli buffer (120 mM 
Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 0.01% bromophenol 
blue) containing 5% of mercaptoethanol, heated at 95˚C for 
5 min, electrophoresed on polyacrylamide gels and transferred 
onto nitrocellulose membranes using the Bio-Rad Mini Trans-
Blot Cell system. The membranes were then washed with 
TBST (50 mM Tris-HCl, pH 7.5, 150 mM NaCl and 0.05% 
Tween-20) and saturated with 5% low fat milk in TBST for 
2 h at room temperature. Incubations with primary antibodies 
were performed for the identification of the different compo-
nents of the PAR complex in 2.5% low fat milk in TBST at 4˚C 
overnight. The polyclonal antibodies raised against PARD3α 
(1:1,000, NBP1-88861; Novus Biologicals), PARD3β (1:1,000, 
Ab122264; Abcam), aPKCι (1:1,000, sc-11399; Santa Cruz 
Biotechnology), PARD6α (1:1,000, sc-25525; Santa Cruz 
Biotechnology), PARD6β (1:1,000, sc-67392; Santa Cruz 
Biotechnology) and PARD6γ (1:2,000, orb35046; Biorbyt, 
Cambridge, UK) were detected with anti-rabbit horseradish 
peroxidase conjugated secondary antibody (1:20,000; Jackson 
ImmunoResearch Laboratories, West Grove, PA, USA). 
Sample loadings in the different western blots were controlled 
Table I. Sequences, genomic positions and amplicon sizes of the primers used in qRT-PCR for the target and reference genes.
Gene Primer sequence Exons Amplicon lenght (bp)
GAPDH Forward: 5'-ATCATCAGCAATGCCTCCTG-3' 6-7 136
 Reverse: 5'-GGCCATCCACAGTCTTCTG-3' 8
RPL13a Forward: 5'-ACCGTGCGAGGTATGCTG-3' 4-5 148
 Reverse: 5'-TAGGCTTCAGACGCACGAC-3' 6
SDHA Forward: 5'-GCATAAGAACATCGGAACTGC-3' 12 147
 Reverse: 5'-GGTCGAACGTCTTCAGGTG-3' 13
aPKCι Forward: 5'-CTAAGGAACGATTGGGTTGTC-3' 16 126
 Reverse: 5'-TGAGAATCAAAGTTGTCCAAACC-3' 17
PARD3α Forward: 5'-GATAATCAGAGGCAGGGGATG-3' 19 115
 Reverse: 5'-TGTGTCTTCTTCCAAGGTCTCC-3' 20
PARD3β Forward: 5'-AACCACCTCTAGGCGAAATG-3' 12 139
 Reverse: 5'-AGAATGTGGTGTTGGAGAAGG-3' 13
PARD6α Forward: 5'-CCTCACCAACGACGACAG-3' 2 107
 Reverse: 5'-AGAGAGTTGGAGGCAAAAGC-3' 3
PARD6β Forward: 5'-TTTCAACGGCCAATCCAC-3' 1 147
 Reverse: 5'-TGTCAGGACGCAATACGTTG-3' 2
PARD6γ Forward: 5'-TCAGACCTTGCGATTCTACG-3' 1 147
 Reverse: 5'-TTGGAGATATGGTGGGTGTG-3' 2
aPKC, atypical protein kinase C; PARD3, partitioning defective 3; PARD6, partitioning defective-6; GAPDH, glyceraldehyde-3-phosphate 
dehydrogenase; RPL13a, ribosomal protein L13a; SDHA, succinate dehydrogenase complex, subunit A.
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with the monoclonal anti-GAPDH (1:20,000, ab8245; Abcam). 
The western blots were revealed by Chemiluminescence 
SuperSignal kit from Pierce (Rockford, IL, USA).
Statistical analysis. First, the Shapiro-Wilk test was used to 
check whether the mRNA data were normally distributed, and 
if they were not, the non-parametric Mann-Whitney U-test 
was used to calculate the statistical significance of differ-
ences in the expression levels of the different PAR complex 
components in female vs. male patients; in classical PTC 
variant vs. other variants; in BRAFV600E mutated vs. wild-type 
PTC; in metastatic (N1) vs. non-metastatic (N0) PTC; in T1-2 
vs. T3-4 tumor sizes; in TNM I-II vs. III-IV stages; in pres-
ence or absence of recurrence; in PTC patients group vs. ATC 
patients group. The correlation of PAR mRNAs with each 
other, and with patient's age was evaluated by the Spearman's 
Rho test. The Cox regression stepwise with backward elimi-
nation analysis was used to assess the independent association 
of patient's age, tumor size, histological variants, lymph 
node metastasis and PAR complex components mRNAs 
with recurrences. The impact of each PAR gene expression 
on disease-free interval was assessed by the Kaplan-Meier 
analysis combined with Mantel-Cox log-rank. For the latter, 
and for the Cox regression, values were classified based on the 
following criteria: fold change >1.2 as ‘increased’; fold change 
<0.8 as ‘decreased’; ≥0.8-fold change ≤1.2 as ‘unvaried’. All 
statistical analyses were carried out with the SPSS software 
(IBM, Armonk, NY, USA) and the results were considered 
significantly different at P-value of <0.05.
Results
Expression of PAR complex components in papillary (PTC) 
and anaplastic (ATC) thyroid cancer tissues. The analyses 
of mRNA levels of PAR complex components in PTC 
samples, compared to normal matched tissues, revealed that 
the expression of all transcripts was deregulated (i.e. reduced 
or increased) in the majority of cases (Fig. 1). In particular, 
aPKCι was reduced in 33/95 (34.7%) cases, unchanged in 
27/95 (28.4%) cases and increased in 35/95 (36.8%) cases; 
PARD3α was reduced in 27/95 (28.4%) cases, unchanged in 
25/95 (26.3%) cases and increased in 35/95 (36.8%) cases; 
PARD3β was reduced in 29/95 (30.5%) cases, unchanged in 
40/95 (42.1%) cases and increased in 26/95 (27.4%) cases; 
PARD6α was reduced in 61/95 (64.2%) cases, unchanged 
in 14/95 (14.7%) cases and increased in 20/95 (21.1%) cases; 
Figure 1. Levels of PAR complex members mRNA in PTC patients. The fold changes were calculated by normalizing the qPCR results from PTC tissues with 
their normal counterpart. In the graph, the small bars indicate the median values, ‘n’ is the number of patients who presented reduced, unchanged and increased 
mRNA values of the investigated genes.
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PARD6β was reduced in 22/95 (23.2%) cases, unchanged in 
20/95 (21.1%) cases and increased in 53/95 (55.8%) cases; and 
PARD6γ was reduced in 63/95 (66.3%) cases, unchanged in 
15/95 (15.8%) cases and increased in 17/95 (17.9%) cases.
We next evaluated whether the expression of the PAR 
genes correlated with each other. As shown in Table II, with 
the exception of the couple PARD6α/PARD6β, a significant 
positive correlation was found between all the mRNAs.
Table II. Correlation analysis among mRNA levels of PAR complex components.
 Correlation coefficients and P-values
 ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
	 aPKCι	 PARD3α PARD3β PARD6α PARD6β PARD6γ
aPKCι 1.000 0.718 0.439 0.279 0.489 0.497
 - <0.0001 <0.0001 0.006 <0.0001 <0.0001
PARD3α  1.000 0.555 0.367 0.507 0.538
  - <0.0001 <0.0001 <0.0001 <0.0001
PARD3β   1.000 0.347 0.570 0.667
   - 0.001 <0.0001 <0.0001
PARD6α    1.000 0.150 0.371
    - 0.142 <0.0001
PARD6β     1.000 0.466
     - <0.0001
PARD6γ      1.000
      -
Figure 2. Comparison of mRNA expression levels of the PAR complex members between PTC and ATC tissues. Messenger RNA level in ATC tissues were 
compared to that of PTC through the ∆∆Ct method. The statistical evaluation of the data was performed with the non-parametric Mann-Whitney test. The 
small bars in the graph indicate the median values.
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The transcripts levels were investigated also in 12 ATC 
tissues. The results showed that the expression of all genes 
analyzed was significantly lower in ATC compared to PTC 
tissues (Fig. 2).
Twelve PTC tissue specimens were used to prepare 
protein extracts, and western blot experiments were carried 
out for the different PAR complex members. The results 
confirmed their deregulation (i.e. reduction or increase) in 
the majority of PTC tissues (Fig. 3). Unfortunately, only 12 
PTC specimens were large enough to permit both RNA and 
proteins extraction, so their number was too small to perform 
any statistical analysis, including the correlation between 
mRNA and protein levels.
BRAFV600E mutation and PAR complex components expres-
sion in PTC tissues. To assess the effect of BRAFV600E mutation 
on PAR complex member expression, we analyzed the mRNA 
levels of each PAR gene in 76 PTC tissues for which it was 
possible to check the BRAF gene status. Of these, 37 (48.7%) 
PTC harbored the BRAFV600E mutation while 39 had the 
wild-type BRAF. The result of univariate analysis, reported in 
Table III, showed that the BRAFV600E mutation associated only 
with PARD6β gene transcription in PTC tissues.
Prognostic relevance of PAR complex member expression 
in PTC patients. No association between the expression, 
at the mRNA level, of PAR complex members and gender, 
age, tumor histology, lymph node metastasis and TNM stage 
was observed (Table III). However, a significant association 
emerged between reduced mRNA levels of aPKCι, PARD3β 
and PARD6γ and increased tumor size (Table III). The univar-
iate statistical analysis evidenced also an association between 
higher PARD6β mRNA levels and BRAFV600E mutation. In 
addition, low levels of PARD3β significantly associated with 
tumor relapse (Table III). Notably, the Kaplan-Meier analysis 
demonstrated a significant correlation only for PARD3β 
mRNA levels with the disease-free interval (DFI) (Fig. 4). 
The latter is represented for patients grouped in three catego-
ries based on the PARD3β mRNA fold changes: increased, 
unvaried and decreased. As evident, lower PARD3β mRNA 
levels negatively influenced the DFI. Besides, the multi-
variate statistical analysis indicated PARD3β and lymph node 
metastasis at diagnosis as the only variables independently 
associated to DFI, with a hazard ratio, respectively, of 3.04 
(95% CI, 1.12-8.24, P=0.029) and 8.21 (95% CI, 1.85-35.53, 
P=0.006) (Table Iv).
Figure 3. Levels of PAR complex proteins in 12 PTC patients. (A) The figure 
shows representative cases of reduced, unvaried and increased protein levels 
in 3 PTC tissues compared to normal matched tissues. (B) The graphic 
shows the distribution of proteins levels into PTC patients tissues normalized 
against their normal counterpart. 
Figure 4. Levels of PARD3β mRNA and disease-free interval (DFI) in PTC 
patients. Kaplan-Meier analysis combined with Mantel-Cox log-rank statis-
tical test, performed on 79 PTC patients followed-up from 5 to 141 months.
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Discussion
Deregulated expression of PAR complex components has 
been associated to cancer development and spread (19). 
Nevertheless, no studies have attempted to investigate their 
expression and role in thyroid cancer progression to date. To 
the best of our knowledge, only one study evidenced the homo-
zygous deletion of PARD3α in primary ATC derived cell lines. 
The authors also reported that the reinstatement of PARD3α 
by exogenous expression was able to reduce cell proliferation, 
motility and invasiveness, and to restore cell-cell contacts and 
cell adhesion (38,39).
In this case study, we analyzed the mRNA levels of the 
paralogous genes encoding for PAR complex components in 
PTC and ATC tissues. The results indicated that the expres-
sion of all these genes was deregulated in PTC, and that all of 
them were significantly lower in ATC compared to PTC. These 
observations may suggest that the reduced expression of PAR 
genes may contribute to TC progression and dedifferentia-
tion, as hypothesized in esophageal squamous cell carcinoma 
where reduced level of PARD3α transcripts was associated 
with tumor dedifferentiation (40). On the other hand, other 
studies reported that the overexpression of PARD3α associates 
with a poor prognosis in patients affected by hepatocellular 
carcinoma or clear cell renal carcinoma (41,42). Concerning 
PARD6α and PARD6β, previous studies in breast cancer 
tissues and cell lines demonstrated an increased expression 
of both genes and their ability to activate the MEK/ERK 
signaling pathway increasing the proliferation rate of breast 
epithelial cells (43,44). However, Cunliffe and colleagues (44) 
reported that the reduced levels of PARD6β protein associated 
with poorly differentiated breast cancer tissues. Regarding 
PARD6γ, our data are in agreement with a study on breast 
cancer cells suggesting for it a tumor suppressor role (45). 
Previous findings on ovarian and lung cancers demonstrated 
an increased expression of aPKCι (46,47). Although also in 
our PTC series aPKCι was found upregulated in 37% of cases, 
it was reduced in 35% of cases and further reduced in ATC 
samples. In interpreting these apparently conflicting data, it 
may be worth to consider that a possible oncogenic/oncosup-
pressive role of PAR components could be context dependent, 
as recently suggested (48-52). However, further functional 
studies should be performed to assess the pathogenetic role of 
each PAR complex component in TC progression.
We next evaluated whether the deregulated expression of 
the different PAR genes could be of any prognostic value. In 
the univariate statistical analysis, some significant associa-
tions emerged with the clinicopathological parameters of PTC 
patients, among which the association between higher PARD6β 
mRNA levels and BRAFV600E mutation. A study conducted in 
mice with BRAF oncogene-dependent PTC demonstrated a 
higher susceptibility to undergo EMT in response to TGFβ in 
the animals with BRAFV600E (53). It was previously demonstrated 
that the BRAFV600E mutation induced the TGFβ secretion by 
PCCl3 cell line, and that TGFR-β phosphorylates PARD6 on 
S345 (54,55). Once phosphorylated, PARD6 induces degrada-
tion of the GTPase RhoA leading to dissolution of TJs, which is 
one of the first steps of the EMT phenomenon (56). Hence, the 
significant association here reported between higher PARD6β 
mRNA levels and BRAFV600E mutation may be a sign of these 
molecular events. However, the most interesting significant 
association emerged by the univariate statistical analysis was 
between the low PARD3β mRNA levels and tumor relapses. 
This result was confirmed by the Kaplan-Meier analysis, and 
multivariate statistical analysis identified the downregulation 
of PARD3β mRNA as an independent prognostic factor for 
DFI. This could be of some clinical relevance since, to date, 
the prognosis of PTC patients still relies on clinicopathological 
variables such as patient's age, tumor size, histology, lymph 
node or distant metastasis, which are not accurate in predicting 
the long-term outcome (57-60). Therefore, the identification of 
new molecular biomarkers strictly related to the risk of PTC 
relapse is sorely needed.
In conclusion, the data here reported, although needing to 
be confirmed by means of larger case-studies, demonstrate 
that the expression of PAR complex members is deregulated in 
the majority of PTC. Besides, there is a general trend towards 
their reduction in ATC tissues, which could be either an effect 
or a cause of the loss of tissue architecture integrity occurring 
in undifferentiated tumors. Functional studies are required 
to assess the actual contribution of PAR complex alterations 
in TC progression and dedifferentiation. Moreover, PARD3β 
mRNA could represent a useful prognostic biomarker for PTC 
patients.
Acknowledgements
The present study was supported by the Sapienza University 
of Rome grants (grant nos. C26A14RNFY and C26N145E4T, 
2014).
References
 1. Cove DJ, Hope IA and Quatrano RS: Polarity in biological systems. 
In: Development Genetics, Epigenetics and Environmental 
Regulation. Russo vEA, Cove DJ, Edgar LG, Jaenish R and 
Salamini F (eds). Springer-verlag, New York, pp507-524, 1999.
 2. Sebbagh M and Borg JP: Insight into planar cell polarity. Exp 
Cell Res 328: 284-295, 2014.
 3. Lee M and vasioukhin v: Cell polarity and cancer - cell and 
tissue polarity as a non-canonical tumor suppressor. J Cell 
Sci 121: 1141-1150, 2008.
 4. Assémat E, Bazellières E, Pallesi-Pocachard E, Le Bivic A 
and Massey-Harroche D: Polarity complex proteins. Biochim 
Biophys Acta 1778: 614-630, 2008.
 5. Khursheed M and Bashyam MD: Apico-basal polarity complex 
and cancer. J Biosci 39: 145-155, 2014.
 6. Lin WH, Asmann YW and Anastasiadis PZ: Expression of 
polarity genes in human cancer. Cancer Inform 14 (Suppl. 3): 
15-28, 2015.
Table Iv. Cox regression stepwise with backward elimination 
analysis.
variables HR 95% CI P-value
Decreased PARD3β mRNA 3.04 1.12-8.24 0.029
Lymph node metastasis 8.21 1.85-35.53 0.006
The table presents only the statistically significant results of the mul-
tivariate analysis of the different clinicopathological parameters and 
PAR complex components mRNAs with cancer recurrence in PTC 
patients. HR, hazard ratio.
INTERNATIONAL JOURNAL OF ONCOLOGY  50:  1413-1422,  2017 1421
 7. Kemphues KJ, Priess JR, Morton DG and Cheng NS: 
Identification of genes required for cytoplasmic localization in 
early C. elegans embryos. Cell 52: 311-320, 1988.
 8. Tepass U, Theres C and Knust E: crumbs encodes an EGF-like 
protein expressed on apical membranes of Drosophila epithelial 
cells and required for organization of epithelia. Cell 61: 787-799, 
1990.
 9. Bilder D and Perrimon N: Localization of apical epithelial deter-
minants by the basolateral PDZ protein Scribble. Nature 403: 
676-680, 2000.
10. Royer C and Lu X: Epithelial cell polarity: A major gatekeeper 
against cancer? Cell Death Differ 18: 1470-1477, 2011.
11. Gandalovičová A, Vomastek T, Rosel D and Brábek J: Cell 
polarity signaling in the plasticity of cancer cell invasiveness. 
Oncotarget 7: 25022-25049, 2016.
12. Lin D, Edwards AS, Fawcett JP, Mbamalu G, Scott JD and 
Pawson T: A mammalian PAR-3-PAR-6 complex implicated 
in Cdc42/Rac1 and aPKC signalling and cell polarity. Nat Cell 
Biol 2: 540-547, 2000.
13. vinot S, Le T, Maro B and Louvet-vallée S: Two PAR6 proteins 
become asymmetrically localized during establishment of 
polarity in mouse oocytes. Curr Biol 14: 520-525, 2004.
14. Louvet-vallée S, vinot S and Maro B: Mitotic spindles and 
cleavage planes are oriented randomly in the two-cell mouse 
embryo. Curr Biol 15: 464-469, 2005.
15. vinot S, Le T, Ohno S, Pawson T, Maro B and Louvet-vallée S: 
Asymmetric distribution of PAR proteins in the mouse embryo 
begins at the 8-cell stage during compaction. Dev Biol 282: 
307-319, 2005.
16. Kohjima M, Noda Y, Takeya R, Saito N, Takeuchi K and 
Sumimoto H: PAR3beta, a novel homologue of the cell polarity 
protein PAR3, localizes to tight junctions. Biochem Biophys Res 
Commun 299: 641-646, 2002.
17. Cline EG and Nelson WJ: Characterization of mammalian Par 6 
as a dual-location protein. Mol Cell Biol 27: 4431-4443, 2007.
18. Dormoy v, Tormanen K and Sütterlin C: Par6γ is at the mother 
centriole and controls centrosomal protein composition through 
a Par6α-dependent pathway. J Cell Sci 126: 860-870, 2013.
19. Ellenbroek SI, Iden S and Collard JG: Cell polarity proteins and 
cancer. Semin Cancer Biol 22: 208-215, 2012.
20. Davies L and Welch HG: Increasing incidence of thyroid cancer 
in the United States, 1973-2002. JAMA 295: 2164-2167, 2006.
21. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer 
statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
22. Kinder BK: Well differentiated thyroid cancer. Curr Opin 
Oncol 15: 71-77, 2003.
23. Pasieka JL: Anaplastic thyroid cancer. Curr Opin Oncol 15: 
78-83, 2003.
24. Nikiforov YE, Biddinger PW and Thompson LDR: Diagnostic 
Pathology and Molecular Genetics of the Thyroid. Lippincott 
Williams & Wilkins, Philadelphia, 2009.
25. Cancer Genome Atlas Research Network: Integrated genomic 
characterization of papillary thyroid carcinoma. Cell 159: 
676-690, 2014.
26. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE 
and Fagin JA: High prevalence of BRAF mutations in thyroid 
cancer: Genetic evidence for constitutive activation of the 
RET/PTC-RAS-BRAF signaling pathway in papillary thyroid 
carcinoma. Cancer Res 63: 1454-1457, 2003.
27. Soares P, Trovisco v, Rocha AS, Lima J, Castro P, Preto A, 
Máximo V, Botelho T, Seruca R and Sobrinho-Simões M: BRAF 
mutations and RET/PTC rearrangements are alternative events 
in the etiopathogenesis of PTC. Oncogene 22: 4578-4580, 2003.
28. Elisei R, Ugolini C, viola D, Lupi C, Biagini A, Giannini R, 
Romei C, Miccoli P, Pinchera A and Basolo F: BRAFv600E 
mutation and outcome of patients with papillary thyroid 
carcinoma: A 15-year median follow-up study. J Clin Endocrinol 
Metab 93: 3943-3949, 2008.
29. Kerjaschki D, Krisch K, Sleyter UB, Umrath W, Jakesz R, 
Depisch D, Kokoschka R and Hörandner H: The structure of 
tight junctions in human thyroid tumors. A systematic freeze-
fracture study. Am J Pathol 96: 207-226, 1979.
30. Fluge Ø, Haugen DR, Lillehaug JR and varhaug JE: Difference 
in patterns of Met expression in papillary thyroid carcinomas and 
nonneoplastic thyroid tissue. World J Surg 25: 623-631, 2001.
31. Bai Y, Kakudo K, Nakamura M, Ozaki T, Li Y, Liu Z, Mori I, 
Miyauchi A and Zhou G: Loss of cellular polarity/cohesiveness 
in the invasive front of papillary thyroid carcinoma and periostin 
expression. Cancer Lett 281: 188-195, 2009.
32. Hedinger C, Williams ED and Sobin LH: The WHO histological 
classification of thyroid tumors: a commentary on the second 
edition. Cancer 63: 908-911, 1989.
33. Barollo S, Pennelli G, vianello F, Watutantrige Fernando S, 
Negro I, Merante Boschin I, Pelizzo MR, Rugge M, Mantero F, 
Nacamulli D, et al: BRAF in primary and recurrent papillary 
thyroid cancers: The relationship with 131I and 2-[18F]fluoro-2-
deoxy-D-glucose uptake ability. Eur J Endocrinol 163: 659-663, 
2010.
34. Chomczynski P and Sacchi N: Single-step method of RNA 
isolation by acid guanidinium thiocyanate-phenol-chloroform 
extraction. Anal Biochem 162: 156-159, 1987.
35. vandesompele J, De Preter K, Pattyn F, Poppe B, van Roy N, 
De Paepe A and Speleman F: Accurate normalization of 
real-time quantitative RT-PCR data by geometric averaging of 
multiple internal control genes. Genome Biol 3, Research0034 
(2002).
36. Ulisse S, Baldini E, Sorrenti S, Barollo S, Prinzi N, Catania A, 
Nesca A, Gnessi L, Pelizzo MR, Mian C, et al: In papillary thyroid 
carcinoma BRAFv600E is associated with increased expression of 
the urokinase plasminogen activator and its cognate receptor, 
but not with disease-free interval. Clin Endocrinol (Oxf) 77: 
780-786, 2012.
37. Livak KJ and Schmittgen TD: Analysis of relative gene 
expression data using real-time quantitative PCR and the 2-ΔΔCT 
method. Methods 25: 402-408, 2001.
38. Bradford MM: A rapid and sensitive method for the quantitation 
of microgram quantities of protein utilizing the principle of 
protein-dye binding. Anal Biochem 72: 248-254, 1976.
39. Garg M, Okamoto R, Nagata Y, Kanojia D, venkatesan S, 
Anand MT, Braunstein GD, Said JW, Doan NB, Ho Q, et al: 
Establishment and characterization of novel human primary 
and metastatic anaplastic thyroid cancer cell lines and their 
genomic evolution over a year as a primagraft. J Clin Endocrinol 
Metab 100: 725-735, 2015.
40. Zen K, Yasui K, Gen Y, Dohi O, Wakabayashi N, Mitsufuji S, 
Itoh Y, Zen Y, Nakanuma Y, Taniwaki M, et al: Defective 
expression of polarity protein PAR-3 gene (PARD3) in esophageal 
squamous cell carcinoma. Oncogene 28: 2910-2918, 2009.
41. Jan YJ, Ko BS, Liu TA, Wu YM, Liang SM, Chen SC, Wang J 
and Liou JY: Expression of partitioning defective 3 (Par-3) for 
predicting extrahepatic metastasis and survival with hepato-
cellular carcinoma. Int J Mol Sci 14: 1684-1697, 2013.
42. Dugay F, Le Goff X, Rioux-Leclerq N, Chesnel F, Jouan F, 
Henry C, Cabillic F, verhoest G, vigneau C, Arlot-Bonnemains Y, 
et al: Overexpression of the polarity protein PAR-3 in clear cell 
renal cell carcinoma is associated with poor prognosis. Int J 
Cancer 134: 2051-2060, 2014.
43. Nolan ME, Aranda v, Lee S, Lakshmi B, Basu S, Allred DC and 
Muthuswamy SK: The polarity protein Par6 induces cell prolif-
eration and is overexpressed in breast cancer. Cancer Res 68: 
8201-8209, 2008.
44. Cunliffe HE, Jiang Y, Fornace KM, Yang F and Meltzer PS: 
PAR6B is required for tight junction formation and activated 
PKCζ localization in breast cancer. Am J Cancer Res 2: 478-491, 
2012.
45. Marques E, Englund JI, Tervonen TA, virkunen E, Laakso M, 
Myllynen M, Mäkelä A, Ahvenainen M, Lepikhova T, Monni O, 
et al: Par6G suppresses cell proliferation and is targeted by 
loss-of-function mutations in multiple cancers. Oncogene 35: 
1386-1398, 2016.
46. Eder AM, Sui X, Rosen DG, Nolden LK, Cheng KW, Lahad JP, 
Kango-Singh M, Lu KH, Warneke CL, Atkinson EN, et al: 
Atypical PKCiota contributes to poor prognosis through loss 
of apical-basal polarity and cyclin E overexpression in ovarian 
cancer. Proc Natl Acad Sci USA 102: 12519-12524, 2005.
47. Regala RP, Weems C, Jamieson L, Khoor A, Edell ES, Lohse CM 
and Fields AP: Atypical protein kinase C iota is an oncogene in 
human non-small cell lung cancer. Cancer Res 65: 8905-8911, 
2005.
48. Iden S, van Riel WE, Schäfer R, Song JY, Hirose T, Ohno S and 
Collard JG: Tumor type-dependent function of the par3 polarity 
protein in skin tumorigenesis. Cancer Cell 22: 389-403, 2012.
49. Yao S, Bee A, Brewer D, Dodson A, Beesley C, Ke Y, 
Ambroisine L, Fisher G, Møller H, Dickinson T, et al: PRKC-ζ 
expression promotes the aggressive phenotype of human prostate 
cancer cells and is a novel target for therapeutic intervention. 
Genes Cancer 1: 444-464, 2010.
TUCCILLI et al:  CELL POLARITY AND THYROID CANCER1422
50. Awadelkarim KD, Callens C, Rossé C, Susini A, vacher S, 
Rouleau E, Lidereau R and Bièche I: Quantification of PKC 
family genes in sporadic breast cancer by qRT-PCR: Evidence 
that PKCι/λ overexpression is an independent prognostic factor. 
Int J Cancer 131: 2852-2862, 2012.
51. Ma L, Tao Y, Duran A, Llado v, Galvez A, Barger JF, Castilla EA, 
Chen J, Yajima T, Porollo A, et al: Control of nutrient stress-
induced metabolic reprogramming by PKCζ in tumorigenesis. 
Cell 152: 599-611, 2013.
52. Namdarian B, Wong E, Galea R, Pedersen J, Chin X, Speirs R, 
Humbert PO, Costello AJ, Corcoran NM and Hovens CM: Loss 
of APKC expression independently predicts tumor recurrence in 
superficial bladder cancers. Urol Oncol 31: 649-655, 2013.
53. Knauf JA, Sartor MA, Medvedovic M, Lundsmith E, Ryder M, 
Salzano M, Nikiforov YE, Giordano TJ, Ghossein RA and 
Fagin JA: Progression of BRAF-induced thyroid cancer is 
associated with epithelial-mesenchymal transition requiring 
concomitant MAP kinase and TGFβ signaling. Oncogene 30: 
3153-3162, 2011.
54. Riesco-Eizaguirre G, Rodríguez I, De la vieja A, Costamagna E, 
Carrasco N, Nistal M and Santisteban P: The BRAFv600E 
oncogene induces transforming growth factor beta secretion 
leading to sodium iodide symporter repression and increased 
malignancy in thyroid cancer. Cancer Res 69: 8317-8325, 2009.
55. Ozdamar B, Bose R, Barrios-Rodiles M, Wang HR, Zhang Y 
and Wrana JL: Regulation of the polarity protein Par6 by 
TGFbeta receptors controls epithelial cell plasticity. Science 307: 
1603-1609, 2005.
56. Gunaratne A, Thai BL and Di Guglielmo GM: Atypical protein 
kinase C phosphorylates Par6 and facilitates transforming 
growth factor β-induced epithelial-to-mesenchymal transition. 
Mol Cell Biol 33: 874-886, 2013.
57. Gospodarowicz MK, Henson DE, Hutter RvP, O'Sullivan B, 
Sobin LH and Wittekind CL: Prognostic Factors in Cancer. 2nd 
edition. Wiley-Liss, New York, 2001.
58. Passler C, Scheuba C, Prager G, Kaczirek K, Kaserer K, 
Zettinig G and Niederle B: Prognostic factors of papillary 
and follicular thyroid cancer: Differences in an iodine-replete 
endemic goiter region. Endocr Relat Cancer 11: 131-139, 2004.
59. Baldini E, Sorrenti S, Tuccilli C, Prinzi N, Coccaro C, Catania A, 
Filippini A, Bononi M, De Antoni E, D'Armiento M, et al: 
Emerging molecular markers for the prognosis of differentiated 
thyroid cancer patients. Int J Surg 12 (Suppl 1): S52-S56, 2014.
60. Ulisse S, Baldini E, Sorrenti S, Barollo S, Gnessi L, Catania A, 
Pellizzo MR, Nardi F, Mian C, De Antoni E, et al: High 
expression of the urokinase plasminogen activator and its cognate 
receptor associates with advanced stages and reduced disease-
free interval in papillary thyroid carcinoma. J Clin Endocrinol 
Metab 96: 504-508, 2011. 
